2-oxo-3-benzoxepins

ABSTRACT

2-Oxo-3-benzoxepin-6a-carboxylic acid derivatives useful as anti-inflammatory agents.

United States Patent Jones 1 June6, 1972 [54] Z-OXO-S-BENZOXEPINS [72] Inventor: Howard Jones, Holrndel, NJ.

[73] Assignee: Merck 8: Co., Inc., Rahway, NJ.

22 Filed: Aug. 19, 1970 211 Appl. No.: 65,354

[52] US. Cl. ..260/343.2 R, 424/279 [51] Int. Cl. .......C07d 9/00 [58] Field of Search Primary Examiner-John M. Ford Attorney-Martin L. Katz, Harry E. Westlake, Jr. and l. Louis Wolk ABSTRACT 2-Oxo-3-benzoxepin-6a-carboxylic acid derivatives useful as anti-inflammatory agents.

2 Claims, No Drawings 1 z-oxo-s-iianzoxsrms wherein R, is hydrogen, methyl, methoxycarbonyL'carboxy, hydroxymethyl, formyl, amino, or methoxycarbonylarnino and R is hydrogen or carboxymethyl.

The compounds of this invention may be prepared by ozonizing a podocarpic ester containing the desired substituents and treating the resultant ozonide with hydrogen peroxide.

The compounds of this invention are useful in the treatment of inflammation. It is believed that the antiinflammatory activity of these compounds is due to the inhibition of complement, a group of nine serum proteins which act sequentially to produce cell destruction and to generate inflammation.

This invention also relates to a method of treating pain, fever or inflammation in patientsv(animal or human) using a compound of formula I. I g The treatment of inflammation in accordance with the method of the present invention is accomplished by topically, orally, rectally or parenterally administering to patients a composition of a compound of Formula I in a non-toxic pharmaceutically acceptable carrier. v I

The non-toxic pharmaceutical carrier may be, for example, either a solid or a liquid. Exemplary of solid carriers are lactose, corn starch, gelatin, talc, sterotix, stearic acid, magnesium stearate, terra alba, sucrose, agar, pectin, cab-o-sil, and

acacia. Exemplary of liquid carriers .are peanut oil, olive oil, sesame oil and water. Similarly, the carrier or diluent may include a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax.

Several pharmaceutical forms of the therapeutically useful compositions can be used. For example, if a-solid carrier is used, the compositions may take the form of tablets, capsules, powders, troches or lozenges, prepared by standard pharmaceutical techniques. If a liquid carrier is used, the preparation may be in the form of a soft gelatin capsule, a syrup, an aqueous solution or a liquid suspension. Suppositories may be prepared in a conventional manner by mixing the compounds of this invention with a suitable non-irritating excipient which is solid at room temperature, but liquid at the rectal temperature. Such materialsare cocoa butter and polyethylene glycol. Gels and lotions for topical application may be prepared in conventional manner.

The active compounds of formula I and of the compositions of this invention are administered in an amount sufficient to treat inflammation, that is to reduce inflammation. Advantageously, the compositions will contain the active ingredient, namely, the compounds of formula I in an amount of from about'50 to 750 mg. per ltg. body weight per day,

preferably from about 250 to 500 mg./kg body weight per day.

The method of treatment of this invention comprises administering to a patient (animal or human), a compound of formula l admixed with a non-toxic pharmaceutical carrier such as exemplified above. The compounds of formula I will be administered in an amount of from 50 mg. to 750 mgJkg. body weight per day, preferablyfrom about 250 mg. to about 500 mg. per kilogram body weight per day. It should be understood, however, that although preferred dosage ranges are given, the dose level for any particular patient depends upon the activity of the specific compound employed. Also many other factors that modify the actions of drugs will be taken into account by those skilled in the an in the therapeutic use of medicinal agents, particularly those of formula I, for example, age, body weight, sex, diet, time of administration, route of administration, rate of excretion, drug combination, reaction sensitivities and severity of the particular disease.

The following examples are presented to further illustrate the invention:

EXAIVIPLE l l -Carboxymethyldeca.hydro-6B,9a,8-dimethyl-2-oxo-3- benzoxepin-wcarboxylic acid Podocarpic acid (4 g.) is dissolved in absolute alcohol (40 ml.) and diazomethane in ether is added until the yellow color persists. The mixtureis allowed to stand for. twelve hours and evaporated to a volume of 10 ml. The reaction mixture is poured into water (200 ml.) and the methyl podocarpate which is precipitated is filtered off.

The product is ozonized at in methanol with 8.5-8.75 p.s.i. pressure of oxygen (0.25 ml./sec. flow rate and volt arc.). The product is poured into a solution consisting of 70 ml. Chlorox, 300 ml. ice-cold water, ml. methanol, 200 g. ice and 10 m1. concentrated hydrochloric acid. The solution is stirred for 20 minutes and extracted with chloroform (3 X 400 ml.). The chloroform solution is dried over magnesium sulfate and evaporated to near dryness. The crude ozonide is treated with 30% hydrogen peroxide solution (50 ml. to an estimated 1.0 g. of ozonide) at 40. The product acid is extracted with ethyl acetate from the dried residue on evaporation. in this way l-carboxymethyldecahydro-6B,9aB-dimethyl-2-oxo-3- benzoxepin-Ga-carboxylic acid, m.p. l98200 is obtained.

EXAMPLE 2 EXAMPLE 3 Decahydro-6B,9a/3-dimethyl-2-oxo-3-benzoxepinl a-carboxaldehyde i 1 ,4a-Dimethyll-hydroxymethyl-6-hydroxyl ,2,3-4,4a, 9,10, IOa-octahydrophenanthrene (1.0 g.) is oxidized with chromic oxide (0.5 g.) in glacial acetic acid (20 ml.) at 50' over 3 hours and then evaporated to 5 ml. It is poured into icewater and the precipitated aldehyde (0.84 g.) is collected and dried.

This aldehyde (0.84 g.) is then ozonized and worked up by the procedure of Example 1 to give decahydr0-6B,9afldimethyl-2-oxo-3-benzoxepin-la-dicarboxaldehyde.

EXAMPLE 4 l ,4a-Dimethyll -hydroxymethyl-6-hydroxyl ,2,3-4,4a, 9,10,10aoctahydrophenanthrene (1.0 g.) is refluxed in concentrated hydrochloric acid (50 ml.) with amalgamated zinc metal (4 g.) for eight hours and then filtered cold. The residue is washed with ethyl acetate and combined washings and filtrates separated. The ethyl acetate is dried and evaporated to give 0.8 g.

This hydrocarbon is then ozonized and worked up by the procedure of Example 1 to give decahydro-6a,6fi,9afltrimethyl-2-oxo-3-benzoxepin.

3 4 EXAMPLE 5 R, o

1-Carboxymethyldecahydro-63,9aB-dimethyl-2-oxo-3- benzoxepin Podocarpic acid (20 g.) is dry distilled under to mm.

pressure and carbon dioxide is given off One fraction is i ozonized and worked up as in Example 1 above. In this way 1- h R w M carboxymethyldecahydro-GB,QaB-dimethyl-2-oxo-3-benzoxw cram 15 hydrogen methyl methoxycarbonyh carboxy' hydroxymethyl, formyl, amino, or methoxycarbonylamino and R is hydrogen or carboxymethyl.

2. A compound as in claim 1 wherein R is carboxy. 1. A compound of the formula:

epin is obtained.

What is claimed is:

l I k 

2. A compound as in claim 1 wherein R1 is carboxy. 